Duloxetine: a new approach for treating stress urinary incontinence

References 

1. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. J Clin Epidemiol. 2000;53:1150–1157
   • Abstract
   • Full Text
   • Full-Text PDF (1008 KB)
   • CrossRef
2. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynecol Obstet. 2003;82:327–338
3. Bø K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. Br Med J. 1999;318:487–493
4. Viktrup L, Bump RC. Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin. 2003;19:485–490
   • MEDLINE
   • CrossRef
5. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al.  Comparative affinity of duloxetine and venlafaxine for serotonin and norepineprine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol. 2001;25:871–880
6. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther. 1995;274:1014–1024
   • MEDLINE
7. Thor K. Targeting serotonin and noradrenaline receptors in stress urinary incontinence. Int J Gynecol Obstet 2004;86(Suppl 1):S41–S55
8. Norton PA, Zinner NR, Yalcin I, Bump RC, for the Duloxetine Urinary Incontinence Study Group. Duloxetine vs. placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002;187:40–48
9. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC, for the Duloxetine Urinary Incontinence Study Group. Duloxetine vs. placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003;170:1259–1263
10. Van Kerrebroeck P, Abrams P, Lange R, Slach M, Wyndaele J-J, Yalcin I, et al.  Duloxetine vs. placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynecol. 2004;111:249–257
11. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC, for the Duloxetine UI Study Group. Duloxetine vs. placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial, BJU Int 2004;93:311–318
12. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology. 1996;47:67–71
    • Abstract
    • Full-Text PDF (620 KB)
    • CrossRef
13. Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology. 1999;53:71–76
    • Abstract
    • Full Text
    • Full-Text PDF (117 KB)
    • CrossRef
14. Donovan JL, Badia X, Corcos J, Kellener C, Naughton M, et al.  Symptom and quality of life assessment. In:  Abrams P,  Cardozo L,  Khoury S,  Wein A editor. Incontinence. Second ed. Plymouth, UK: Health Publication Ltd; 2002;p. 267–316
15. Guy W. In: EGDEU assessment manual for psychopharmacology. Rockville (MD): National Institute of Mental Health, US Department of Health, Education, and Welfare; 1976;p. 218–222
16. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189:98–101
    • Abstract
    • Full Text
    • Full-Text PDF (58 KB)
    • CrossRef
17. Drutz HP, Cardozo L, Baygani SK, Bump RC. Duloxetine treatment of women with pure urodynamic stress incontinence awaiting continence surgery. Int J Gynecol Obstet. 2003;83(Suppl 3):34; abs. FC2.7.2
18. Cardozo L, Drutz HP, Baygani SK, Bump RC. Duloxetine response and onset of action in women with severe stress urinary incontinence (SUI) awaiting continence surgery. Int J Gynecol Obstet. 2003;83(Suppl 3):34; abs. FC2.7.3
19. Moore KH, Hay D, Imrie A, Watson A, Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 1990;66:479–485
    • MEDLINE
    • CrossRef
20. Dubeau CE, Khullar V. Drug impact on the SUI component of mixed incontinence: is its all placebo effect? Presented at the 2002 American Urogynecologic Society Meeting, San Francisco
21. Ramsay IN, Thou M. A randomised, double-blind, placebo controlled trial of pelvic floor exercises in the treatment of genuine stress incontinence. Neurourol Urodyn. 1990;9:398–399
22. Yalcin I, Bump R. The effect of prior treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Neurourol Urodyn. 2003;22:481–482 abs. 83
23. Moore KH, O'Sullivan RJ, Simons A, Prashar S, Anderson P, Louey M. Randomised controlled trial of nurse continence advisor therapy compared with standard urogynaecology regimen for conservative incontinence treatment: efficacy, costs and two year follow up. Br J Obs Gynaecol. 2003;110:649–657
24. Beck A, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, Texas: Psychological Corp; 1996;